Authors
Catherine F Siengsukon, Lauren K Hand, Eryen Nelson, Allison Glaser, Rebecca Ludwig, Julia A Russell, Milind A Phadnis, Junqiang Dai, Jared Bruce, Eric D Vidoni, Michelle Drerup, Jill Morris, Jeffrey M Burns
Published in
Alzheimer's & dementia : the journal of the Alzheimer's Association. Volume 22. Issue 6. Pages e71591.
Abstract
Insomnia is associated with increased risk for Alzheimer's disease (AD). It is unknown how cognitive behavioral therapy for insomnia (CBT-I) impacts two hallmarks of AD progression, cognitive performance and beta-amyloid (Aβ) burden.
Cognitively normal older adults with symptoms of insomnia were randomized into CBT-I treatment (n = 100) or control (n = 100) groups. Cognitive performance was assessed at baseline, 6-weeks, and 1-year (1 year). Aβ burden was assessed in a subsample (n = 50).
No differences were observed between groups in change in cognitive performance, including speed of information processing (mean difference, 0.017; 95% confidence interval [CI], -0.1036 to 0.1376; p = 0.78), executive function (-0.0881; 95% CI, -0.2945 to 0.1182; p = 0.40), and memory (0.4068; 95% CI, -2.3965 to 3.2101; p = 0.77). No group differences were observed in Aβ deposition.
CBT-I did not improve cognitive performance or Aβ deposition by one year. Longer follow up is needed to understand the potential impact of CBT-I on AD risk.
The study was registered on clinicaltrials.gov (NCT03954210) on 5/17/2019.
PMID:
42298279
Bibliographic data and abstract were imported from PubMed on 16 Jun 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 12
- Comments 0